Ambu (AMBU) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic direction and market positioning

• Achieved strong double-digit growth, outpacing MedTech industry averages, and successfully executed a turnaround strategy.

• Focused on advancing from single-use endoscopy leadership to global endoscopy leadership, with a new strategy emphasizing respiratory and urology.

• Single-use endoscopy market is expected to grow over 20% annually to 2030, with significant white space for further penetration.

• EndoIntelligence platform enables cross-application innovation and operational efficiency across product lines.

• Strategic choices include prioritizing respiratory and urology, continued growth in ENT, and a long-term approach to GI.

Innovation, technology, and product development

• Broadest single-use endoscope platform, all built on a unified software system for easier hospital integration and innovation.

• Ongoing development of next-generation bronchoscopes, cystoscopes, and mobile video laryngoscopes, with strong adoption in key markets.

• AI and software enhancements improve image quality, procedure efficiency, and clinical documentation.

• Investments in disruptive technologies and partnerships to accelerate innovation and address complex procedures.

• Scalable manufacturing, especially in Mexico, supports cost efficiency and geopolitical resilience.

Financial performance and outlook

• Organic revenue CAGR of 11%-13% targeted over the next five years, with endoscopy expected to grow even faster.

• EBIT margin improved from 2.7% to 12% in two years, with a goal to exceed 20% by 2027-2028, balancing growth investments and efficiency.

• FY guidance: 10%-13% revenue growth, 12%-14% EBIT margin, with higher growth in endoscopy and normalized growth in legacy segments.

• Strong cash generation and no debt support ongoing investments and potential M&A.

• M&A focus is on complementary technologies and devices, with careful attention to long-term margin impact.